We use cookies for a better user experience. Read our Privacy Policy

I Agree

Meningococcal Vaccines Market

Meningococcal Vaccines Market (Type: Polysaccharide, Conjugate Vaccines, Combination Vaccines, Men B Vaccine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Meningococcal Vaccines Market Outlook 2031

  • The meningococcal vaccines market was valued at US$ 4.2 Bn in 2021
  • It is estimated to expand at a CAGR of 9.4% from 2022 to 2031
  • The meningococcal vaccines market is expected to reach a value of US$ 9.2 Bn by the end of 2031

Analysts’ Viewpoint on Meningococcal Vaccines Market Scenario

High rate of adoption of meningococcal vaccine can be ascribed to the rise in awareness about the treatment avenues of meningococcal meningitis. This rare disease can lead to serious complications; it has a high fatality rate when left untreated. This type of meningitis is spread through contact with respiratory droplets and may have asymptomatic carriers. It also causes an infection in the lining of the brain as well as the spinal cord. Increase in number of ongoing clinical programs for meningococcal vaccines at various stages of development around the world provides significant opportunities for market participants. Companies focusing on assessing the potential of existing meningococcal vaccines for expanded age indications are likely to consolidate their position in the market. Moreover, rise in marketing approvals around the world is driving the global market.

meningococcal vaccines market

Overview of Meningococcal Vaccines Market

Meningococcal vaccines are used to prevent diseases such as meningitis, meningococcemia, and septicemia caused due to N. meningitides. Meningococcal disease, especially meningococcal meningitis, is highly infectious among individuals or communities. Several meningococcal serogroups have been identified to date; of these, serogroups A, B, C, Y, and W-135 are the most prominent ones causing the infection. Rise in prevalence of meningococcal meningitis has recently emerged as a public health concern. Several meningococcal infection treatment options are available around the world; however, the disease still claims several lives.

Meningococcal disease is spread through contact with secretions from the nose and throat (saliva or spit). Kissing, sharing silverware, drinking from the same container, sharing a cigarette or lipstick, coughing, and having close social contact (living in the same house) are examples of how the disease spreads. Vaccination is one of the most effective ways to prevent meningococcal disease.

Request a sample to get extensive insights into the Meningococcal Vaccines Market

Rise in Prevalence of Meningitis to Drive Global Meningococcal Vaccines Market

Meningococcal disease is infrequent; however, it has a fatality rate between 5% and 15%. If left untreated, it frequently leads to serious complications. Meningococcal meningitis causes an infection of the brain and spinal cord lining. It has the potential to cause large epidemics and endemics. Each year, approximately 10 to 15 of every 100 people infected with meningococcal disease die. One in every five survivors is likely to suffer from permanent disabilities such as deafness, brain damage, limb loss, or seizures. Hence, demand for meningitis vaccines is increasing around the globe.

Increase in Awareness about Disease and Growth in Marketing Approvals to Boost Market

The National Meningitis Association (NMA) encourages collaboration by offering opportunities to work with government agencies, corporations, and other non-profit organizations in order to raise awareness about meningococcal disease, its prevention, and the critical need for immediate treatment after diagnosis. Increase in coverage rate of immunization programs around the world is likely to increase access to vaccines. The Meningitis Foundation of America (MFA) is a non-profit organization that provides information and support to people who suffer from meningitis. The foundation also aims to raise public and medical awareness about the early symptoms of meningitis. Thus, the meningococcal vaccines market is estimated to expand at a steady pace during the forecast period.

Request a custom report on Meningococcal Vaccines Market

Rise in Sale of Meningococcal Conjugate Vaccines in Developing Countries to Fuel Market

Based on type, the conjugate vaccine segment is projected to dominate the market and account for 62% share by 2031. The benefits of meningococcal conjugate vaccines, such as long-lasting immunity, immunologic memory, avidity, and herd immunity, are driving sales. This trend is expected to continue during the forecast period. Conjugate vaccines are extensively used in mass vaccination campaigns in affected areas such as Africa. Moreover, they have the ability to increase antibody persistence. Various meningococcal conjugate vaccine programs have been introduced around the world over the last few decades. The vaccine has significantly reduced the incidence of meningococcal disease since 2010. The recently introduced serogroup C conjugate vaccine is safe and effective even in the youngest children. Vaccines against group B meningococci have shown modest efficacy in both children and adults.

Government Support and High R&D investments Boosting Market in North America

North America dominated the global meningococcal vaccines market in 2021. The market in the region is anticipated to expand at a notable CAGR from 2022 to 2031. Government recommendations and support, and high R&D investments are driving the market in North America. The U.S. is expected to be a prominent market for meningococcal vaccines in North America due to the rise in disease awareness and improved health care infrastructure in the country. Meningococcal disease has been declining in the U.S. since the 1990s. According to the Centers for Disease Control and Prevention (CDC), approximately 350 cases of meningococcal disease were reported in 2017. Furthermore, awareness among the general public is increasing. The meningococcal vaccines market in Asia Pacific is projected to grow at a rapid pace due to the presence of a large population, improved access to health care systems, and increase in awareness about the meningococcal disease in the region.

Analysis of Key Players in Global Meningococcal Vaccines Market

The global meningococcal vaccines market is fragmented, with a large number of large-scale vendors controlling a majority of the share. Most of the firms are investing significantly in comprehensive research and development activities. Expansion of product portfolios and mergers and acquisitions are major strategies adopted by key players. Market players are focusing on key trends in meningococcal vaccines with the help of recent R&D insights.

Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. are the prominent entities operating in the market. Each of these players has been profiled in the meningococcal vaccines market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.

Key Developments in Global Meningococcal Vaccines Market

  • In January 2022, CanSino Biologics Inc. announced that the National Medical Products Administration of China ("NMPA") approved its ACYW135 Meningococcal Conjugate Vaccine (MCV4, trade name: MenhyciaTM), making it the first of its kind in China. MenhyciaTM covalently binds common pathogenic meningococcal serogroups A, C, W135, and Y to the carrier protein CRM197.
  • In April 2020, The U.S. FDA approved a Biologics License Application for Sanofi's MenQuadfiTM meningococcal conjugate vaccine for the prevention of invasive meningococcal disease in children aged two years and older. MenQuadfi was developed to elicit and demonstrate a high immune response across all four serogroups for a wide range of ages, and it was well tolerated. MenQuadfi is designed to protect a broader age range.
  • In April 2018, Pfizer Inc announced that TRUMENBA (Meningococcal Group B Vaccine) received FDA Breakthrough Therapy designation for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children aged 1 to 9 years. This is the first time a MenB vaccine has been designated as a Breakthrough Therapy to help protect children as young as one year old. TRUMENBA was previously designated as a Breakthrough Therapy in 2014 for the prevention of MenB in adolescents and young adults aged 10 to 25 years, and later that year received the FDA approval as the first MenB vaccine in the U.S.

Meningococcal Vaccines Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 4.2 Bn

Market Forecast Value in 2031

US$ 9.2 Bn

Growth Rate (CAGR)

9.4%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Polysaccharide
      • Menomune
      • Mencevax
      • NmVac4
      • Others
    • Conjugate Vaccines
      • Menactra
      • Menveo
      • NeisVac-C
      • Nimenrix
      • Meningitec
      • Menjugate
      • MenAfriVac
      • NmVac4-DT
    • Combination Vaccines
      • MenHibrix
      • Menitorix
    • Men B Vaccines
      • Bexsero
      • Trumenba
  • End-user
    • Retail Pharmacies
    • Hospital Pharmacies
    • Others (online pharmacies, drug stores)

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia & CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa

Companies Profiled

  • Sanofi SA
  • Novartis International
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Nuron Biotech
  • JN-International Medical Corporation
  • Serum Institute of India Ltd
  • Baxter International
  • Biomed Pvt. Ltd

Customization Scope

Available upon request

Pricing

Available upon request

Meningococcal Vaccines Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global meningococcal vaccines market in 2021?

The global meningococcal vaccines market was valued at US$ 4.2 Bn in 2021

How big will be the meningococcal vaccines market in 2031?

The global meningococcal vaccines market is projected to reach US$ 9.2 Bn by 2031

What will be the CAGR of the global meningococcal vaccines market during the forecast period (2022-2031)?

The global meningococcal vaccines market is anticipated to record a CAGR of 9.4% from 2022 to 2031

What are the prominent trends impacting the market growth?

Growth in prevalence of meningitis, rise in disease awareness, and increase in marketing approvals are prominent trends driving the market

What was the market share of the leading segment of the global meningococcal vaccines market in 2021?

The conjugate vaccine type segment held over 60% share of the global meningococcal vaccines market in 2021

Which region would hold a major market share during the forecast period?

North America is expected to hold a major share of the global market during the forecast period

Who are the prominent players in the meningococcal vaccines market?

Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Meningococcal Vaccines Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Regulatory Scenario by Region/globally

    5.3. Covid-19 Impact analysis

6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

        6.3.1. Polysaccharide

            6.3.1.1. Menomune

            6.3.1.2. Mencevax

            6.3.1.3. NmVac4

            6.3.1.4. Others

        6.3.2. Conjugate Vaccines

            6.3.2.1. Menactra

            6.3.2.2. Menveo

            6.3.2.3. NeisVac-C

            6.3.2.4. Nimenrix

            6.3.2.5. Others

        6.3.3. Combination Vaccines

            6.3.3.1. MenHibrix

            6.3.3.2. Menitorix

        6.3.4. Men B Vaccines

            6.3.4.1. Bexsero

            6.3.4.2. Trumenba

    6.4. Global Meningococcal Vaccines Market Attractiveness, by Type

7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

        7.3.1. Retail Pharmacies

        7.3.2. Hospital Pharmacies

        7.3.3. Others (online pharmacies, drug stores)

    7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user

8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Meningococcal Vaccines Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region

9. North America Meningococcal Vaccines Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

        9.2.1. Polysaccharide

            9.2.1.1. Menomune

            9.2.1.2. Mencevax

            9.2.1.3. NmVac4

            9.2.1.4. Others

        9.2.2. Conjugate Vaccines

            9.2.2.1. Menactra

            9.2.2.2. Menveo

            9.2.2.3. NeisVac-C

            9.2.2.4. Nimenrix

            9.2.2.5. Others

        9.2.3. Combination Vaccines

            9.2.3.1. MenHibrix

            9.2.3.2. Menitorix

        9.2.4. Men B Vaccines

            9.2.4.1. Bexsero

            9.2.4.2. Trumenba

    9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

        9.3.1. Retail Pharmacies

        9.3.2. Hospital Pharmacies

        9.3.3. Others (online pharmacies, drug stores)

    9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Meningococcal Vaccines Market Attractiveness Analysis

        9.5.1. By Type

        9.5.2. By End-user

        9.5.3. By Country

10. Europe Meningococcal Vaccines Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

        10.2.1. Polysaccharide

            10.2.1.1. Menomune

            10.2.1.2. Mencevax

            10.2.1.3. NmVac4

            10.2.1.4. Others

        10.2.2. Conjugate Vaccines

            10.2.2.1. Menactra

            10.2.2.2. Menveo

            10.2.2.3. NeisVac-C

            10.2.2.4. Nimenrix

            10.2.2.5. Others

        10.2.3. Combination Vaccines

            10.2.3.1. MenHibrix

            10.2.3.2. Menitorix

        10.2.4. Men B Vaccines

            10.2.4.1. Bexsero

            10.2.4.2. Trumenba

    10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

        10.3.1. Retail Pharmacies

        10.3.2. Hospital Pharmacies

        10.3.3. Others (online pharmacies, drug stores)

    10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis

        10.5.1. By Type

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

        11.2.1. Polysaccharide

            11.2.1.1. Menomune

            11.2.1.2. Mencevax

            11.2.1.3. NmVac4

            11.2.1.4. Others

        11.2.2. Conjugate Vaccines

            11.2.2.1. Menactra

            11.2.2.2. Menveo

            11.2.2.3. NeisVac-C

            11.2.2.4. Nimenrix

            11.2.2.5. Others

        11.2.3. Combination Vaccines

            11.2.3.1. MenHibrix

            11.2.3.2. Menitorix

        11.2.4. Men B Vaccines

            11.2.4.1. Bexsero

            11.2.4.2. Trumenba

    11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

        11.3.1. Retail Pharmacies

        11.3.2. Hospital Pharmacies

        11.3.3. Others (online pharmacies, drug stores)

    11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis

        11.5.1. By Type

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America Meningococcal Vaccines Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

        12.2.1. Polysaccharide

            12.2.1.1. Menomune

            12.2.1.2. Mencevax

            12.2.1.3. NmVac4

            12.2.1.4. Others

        12.2.2. Conjugate Vaccines

            12.2.2.1. Menactra

            12.2.2.2. Menveo

            12.2.2.3. NeisVac-C

            12.2.2.4. Nimenrix

            12.2.2.5. Others

        12.2.3. Combination Vaccines

            12.2.3.1. MenHibrix

            12.2.3.2. Menitorix

        12.2.4. Men B Vaccines

            12.2.4.1. Bexsero

            12.2.4.2. Trumenba

    12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

        12.3.1. Retail Pharmacies

        12.3.2. Hospital Pharmacies

        12.3.3. Others (online pharmacies, drug stores)

    12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis

        12.5.1. By Type

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

        13.2.1. Polysaccharide

            13.2.1.1. Menomune

            13.2.1.2. Mencevax

            13.2.1.3. NmVac4

            13.2.1.4. Others

        13.2.2. Conjugate Vaccines

            13.2.2.1. Menactra

            13.2.2.2. Menveo

            13.2.2.3. NeisVac-C

            13.2.2.4. Nimenrix

            13.2.2.5. Others

        13.2.3. Combination Vaccines

            13.2.3.1. MenHibrix

            13.2.3.2. Menitorix

        13.2.4. Men B Vaccines

            13.2.4.1. Bexsero

            13.2.4.2. Trumenba

    13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

        13.3.1. Retail Pharmacies

        13.3.2. Hospital Pharmacies

        13.3.3. Others (online pharmacies, drug stores)

    13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis

        13.5.1. By Type

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2021

    14.3. Company Profiles

        14.3.1. Sanofi SA

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. SWOT Analysis

            14.3.1.4. Strategic Overview

        14.3.2. Novartis International

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. SWOT Analysis

            14.3.2.4. Strategic Overview

        14.3.3. GlaxoSmithKline plc

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. SWOT Analysis

            14.3.3.4. Strategic Overview

        14.3.4. Pfizer Inc.

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. SWOT Analysis

            14.3.4.4. Strategic Overview

        14.3.5. Nuron Biotech.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. SWOT Analysis

            14.3.5.4. Strategic Overview

        14.3.6. JN-International Medical Corporation.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. SWOT Analysis

            14.3.6.4. Strategic Overview

        14.3.7. Serum Institute of India Ltd

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Product Portfolio

            14.3.7.3. SWOT Analysis

            14.3.7.4. Strategic Overview

        14.3.8. Baxter International

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Product Portfolio

            14.3.8.3. SWOT Analysis

            14.3.8.4. Strategic Overview

List of Tables

Table 01: Global Meningococcal Vaccine Market Pipeline Analysis

Table 02: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

Table 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide Meningococcal Vaccines, 2022–2031

Table 04: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Meningococcal Vaccines, 2022–2031

Table 05: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Meningococcal Vaccines, 2022–2031

Table 06: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Meningococcal Vaccines, 2022–2031

Table 07: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 08: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Region, 2022–2031

Table 09: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country, 2022–2031

Table 10: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

Table 11: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

Table 12: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

Table 13: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

Table 14: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

Table 15: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 16: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 17: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

Table 18: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

Table 19: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

Table 20: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

Table 21: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

Table 22: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 23: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 24: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

Table 25: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

Table 26: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

Table 27: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

Table 28: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

Table 29: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 30: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 31: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

Table 32: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

Table 33: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

Table 34: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

Table 35: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

Table 36: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

Table 37: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

Table 38: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

Table 39: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

Table 40: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

Table 41: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

Table 42: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

Table 43: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

List of Figures

Figure 01: Global Meningococcal Vaccines Market Size (US$ Bn) and Distribution, by Region, 2022 and 2031

Figure 02: Market Snapshot of Global Meningococcal Vaccines Market

Figure 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

Figure 04: Market Value Share, by Type, 2021

Figure 05: Market Value Share, by End-user, 2021

Figure 06: Market Value Share, by Region, 2021

Figure 07: Global Meningococcal Vaccines Market Value Share Analysis, by Type, 2022 and 2031

Figure 08: Global Meningococcal Vaccines Market Attractiveness, by Type2022–2031

Figure 09: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by   Polysaccharide Vaccines, 2022–2031

Figure 10: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2022–2031

Figure 11: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, Combination Vaccines, 2022–2031

Figure 12: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Men B Vaccines, 2021

Figure 13: Global Meningococcal Vaccines Market Value Share Analysis, by End-user, 2022 and 2031

Figure 14: Global Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

Figure 15: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2022–2031

Figure 16: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2022–2031

Figure 17: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022–2031

Figure 18: Global Meningococcal Vaccines Market Value Share (%), by Region, 2022 and 2031

Figure 19: Global Meningococcal Vaccines Market Attractiveness, by Region2022–2031

Figure 20: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

Figure 21: North America Meningococcal Vaccines Market Value Share (%), by Country, 2022 and 2031

Figure 22: North America Meningococcal Vaccines Market Attractiveness, by Country2022–2031

Figure 23: North America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

Figure 24: North America Meningococcal Vaccines Market Attractiveness, by Type2022–2031

Figure 25: North America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

Figure 26: North America Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

Figure 27: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

Figure 28: Europe Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

Figure 29: Europe Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

Figure 30: Europe Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

Figure 31: Europe Meningococcal Vaccines Market Attractiveness, by Type2022–2031

Figure 32: Europe Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

Figure 33: Europe Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

Figure 34: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

Figure 35: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

Figure 36: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

Figure 37: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

Figure 38: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Type2022–2031

Figure 39: Asia Pacific Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

Figure 40: Asia Pacific Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

Figure 41: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

Figure 43: Latin America Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

Figure 45: Latin America Meningococcal Vaccines Market Attractiveness, by Type2022–2031

Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

Figure 47: Latin America Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

Figure 48: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

Figure 49: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

Figure 50: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

Figure 51: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

Figure 52: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Type2022–2031

Figure 53: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

Figure 54: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

Figure 55: Global Meningococcal Vaccines Market Share, by Company, 2018

Figure 56: Baxter International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016–2018

Figure 57: Baxter International, Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 58: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016–2018

Figure 59: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 60: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2021

Figure 61: Novartis AG Breakdown of Net Sales, by Region, 2021

Figure 62: Novartis AG Breakdown of Net Sales, by Business Segment, 2021

Figure 63: Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2021

Figure 64: Sanofi S.A Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2021

Figure 65: Sanofi S.A Breakdown of Net Sales (%), by Business Segment, 2021

Figure 66: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2021

Figure 67: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

838

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved